Drug Trial Radar · NCT03737851
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Dec 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
208
Actual
Start
Dec 11, 2018
Primary completion
Aug 9, 2021
Study completion Sep 9, 2021
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
Conditions
- Multiple Sclerosis (MS)
Interventions
elezanumabDrug
solution for infusion
placeboDrug
solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Overall Response Score (ORS) at Week 52Time frame: Week 52
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Main /ID# 204618
Birmingham, Alabama
St. Josephs Hospital and Med Center /ID# 204197
Phoenix, Arizona
Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249
Berkeley, California
The Research Center of Southern California /ID# 204269
Carlsbad, California
Vladimir Royter MD /ID# 204392
Hanford, California
UC Irvine Health /ID# 205728
Irvine, California
Stanford MS Center /ID# 204283
Palo Alto, California
UC Davis Health-Neurological Surgery /ID# 204188
Sacramento, California
UCSF School of Medicine - Neurology /ID# 204251
San Francisco, California
University of Colorado School of Medicine /ID# 204250
Aurora, Colorado
Advanced Neurosciences Research, LLC /ID# 204289
Fort Collins, Colorado
The University of Chicago Medical Center /ID# 205319
Chicago, Illinois
Indiana Univ School Medicine /ID# 204891
Indianapolis, Indiana
Rowe Neurology Institute /ID# 204391
Lenexa, Kansas
The NeuroMedical Center /ID# 204253
Baton Rouge, Louisiana
Ochsner Medical Center /ID# 204189
New Orleans, Louisiana
Duplicate_Parexel International /ID# 204273
Baltimore, Maryland
International Neurorehabilitation Institute /ID# 213332
Lutherville, Maryland
Pediatric Endocrine Associates /ID# 204279
Boston, Massachusetts
Michigan Institute for Neurological Disorders (MIND) /ID# 204194
Farmington Hills, Michigan
Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328
Owosso, Michigan
Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383
Chaska, Minnesota
Washington University-School of Medicine /ID# 204388
St Louis, Missouri
The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433
St Louis, Missouri
Cleveland Clinic Lou Ruvo Cent /ID# 204745
Las Vegas, Nevada
Oklahoma Med Res. Foundation /ID# 204389
Oklahoma City, Oklahoma
Providence Neurological Specialties - West /ID# 204248
Portland, Oregon
Thomas Jefferson University /ID# 204281
Philadelphia, Pennsylvania
Advanced Neurosciences Institute /ID# 204557
Franklin, Tennessee
KCA Neurology - Franklin /ID# 204208
Franklin, Tennessee
Tri-State Mountain Neurology /ID# 204252
Johnson City, Tennessee
Neurology Consultants of Dallas - LBJ Fwy /ID# 204398
Dallas, Texas
UT HSC Multiple Sclerosis Research Group - Houston /ID# 206418
Houston, Texas
Dr. Bhupesh Dihenia, MD, PA /ID# 207839
Lubbock, Texas
Central Texas Neurology Consul /ID# 204268
Round Rock, Texas
Integrated Neurology Services, PLLC /ID# 204261
Alexandria, Virginia
Evergreen Neuroscience Institute /ID# 204203
Kirkland, Washington
Virginia Mason Medical Center /ID# 205440
Seattle, Washington
Swedish MS Center /ID# 204198
Seattle, Washington
University of Washington Medicine MS Center /ID# 205852
Seattle, Washington
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.